Therapeutics, Inc. (NASDAQ:OSIR), announced today that the
manuscript from its multi-center (n=20), randomized, controlled clinical
trial comparing the safety and effectiveness of Grafix® to control in
patients with chronic diabetic foot ulcers (DFUs) has been accepted for
publication in the International Wound Journal.
for Grafix® Manuscript from Osiris’ Multi-center, Randomized, Controlled Clinical Trial Accepted in Peer-Reviewed Journal investment picks